1. Guest, the 'News in Brief' post for w/c 11th Feb is here.
    Dismiss Notice

Immunosignature Analysis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) (2018) Fluge et al.

Discussion in 'BioMedical ME/CFS Research' started by Cheshire, Oct 10, 2018.

  1. Cheshire

    Cheshire Moderator Staff Member

    Messages:
    1,163
    Likes Received:
    10,039
    https://link.springer.com/article/10.1007/s12035-018-1354-8

    Edit: Text breaks are mine.
     
    Last edited: Oct 10, 2018
    JaimeS, inox, MEMarge and 21 others like this.
  2. Alvin

    Alvin Senior Member (Voting Rights)

    Messages:
    2,576
    Likes Received:
    12,677
    Does this mean that 256 tests need to be done to differentiate ME from controls or one molecule that has 256 parts in it?
     
    andypants, Inara and adambeyoncelowe like this.
  3. Jonathan Edwards

    Jonathan Edwards Senior Member (Voting Rights)

    Messages:
    3,257
    Likes Received:
    35,647
    I assume that they have 256 different peptide molecules, a tiny dab of each of which is put on to a different pin or well in an array.The patient's serum is then added and the pattern of antibody binding to the 256 pins (wells) is visualised using a fluorescent or otherwise tagged developer reagent. So each patient and control provides a pattern of 256 spots of different brightness. You put these into computer and it tells you whether it is a patient pattern or a control pattern - like a barcode really.

    What the text quoted above does not say is how well the pattern replicated across populations. With enough dots in the array you can always find a signature for patients, but it may be just a chance pattern in that sample.
     
    TiredSam, Simon M, veganmua and 15 others like this.
  4. Alvin

    Alvin Senior Member (Voting Rights)

    Messages:
    2,576
    Likes Received:
    12,677
    Interesting, thanks for explaining
     
  5. Hutan

    Hutan Moderator Staff Member

    Messages:
    3,395
    Likes Received:
    15,252
    One group of samples were from the earlier rituximab trials.

    So presumably one thing to watch out for will be another paper that applies the same protocol to generate immunosignatures from the post-treatment samples, to see if there are any interesting differences between the responders and non-responders and if the responders' immunosignatures look more like those of the healthy controls. Sample sizes are small of course.
     
    veganmua, inox, ukxmrv and 3 others like this.

Share This Page